Mind-Body Practices Can Shift Stress Biomarkers—With Limits

Mind-body practices can move stress-related biomarkers, but they are not proven anti-inflammatory drugs in yoga pants. A 2025 systematic review and meta-analysis by Lee et al. pooled 89 randomized controlled trials and found a consistent overall direction: cortisol and several pro-inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α), tended to fall, while brain-derived neurotrophic factor (BDNF) tended to rise.

That is meaningful evidence that behavioral practices can affect stress biology. It does not show that every form of meditation, yoga, breathing practice, or mindfulness training creates the same biological response—or that any biomarker change improves lifespan, prevents disease, or replaces medical care. The pooled results varied substantially across interventions, populations, control groups, and the timing of measurements.

What the 89-trial review found

Lee and colleagues examined randomized trials of static mind-body interventions such as mindfulness-based stress reduction, mindfulness-based cognitive therapy, acceptance and commitment therapy, and meditation; movement-based practices including qigong, tai chi, and yoga; and several clinical contexts. Their biomarker panel included CRP, IL-6, TNF-α, other cytokines, nuclear factor kappa B, salivary immunoglobulin A, BDNF, and cortisol.

The analysis used random-effects standardized mean differences and stratified results by intervention type, clinical context, and control type. That structure matters. A cortisol measurement in a stressed healthy adult after mindfulness training does not answer the same question as an inflammatory marker in a person with cancer or neurological disease. Nor is a waitlist comparator equivalent to a group program that provides therapist contact, expectation, social support, and a scheduled hour of calm.

Several biomarker analyses had I² values above 50%, the review's threshold for substantial heterogeneity. In practical terms, the average effect combines studies that may be measuring different biological states at different moments. The review supports a directional signal. It does not establish one uniform neuroendocrine-immune signature.

Extreme illness provides a useful, imperfect test

A 2021 randomized trial by Koehler et al. tested that signal in palliative-care patients with terminal cancer, a population facing unusually high physical and emotional stress. Participants received three 20- to 30-minute sessions of either biographical music therapy—live performances of personally selected songs—or an active relaxation and mindfulness control.

At the second session, both groups showed reductions in salivary cortisol and heart rate, with no between-group biomarker difference. Researchers also measured salivary alpha-amylase, a marker related to sympathetic-adrenal-medullary activity, and heart-rate variability (HRV) by photoplethysmography.

The result supports a narrower conclusion than "music therapy and mindfulness work through the same pathway." Both structured interventions coincided with lower cortisol and heart rate in a high-stress clinical setting. Because the comparator was active, the trial cannot credit those changes specifically to mindfulness content. Therapeutic attention, reduced immediate arousal, and the quiet structure of a session could all contribute.

The study also cautions against treating a lower heart rate as proof of stronger vagal tone. Prior palliative-care studies cited by the authors found no HRV change after brief standardized mindfulness, even where heart rate fell. In terminal illness, medications, dry mouth, nausea, and attrition can further complicate salivary sampling and interpretation.

Stress responses have phases, not one switch

A 2022 controlled study by Gamaiunova et al. compared two mindfulness-based interventions across anticipation, reactivity, and recovery phases of a stress response, while assessing several physiological systems. The effects differed by both phase and system.

This is one of the strongest reasons to resist simple "cortisol down, inflammation down" narratives. An intervention might alter anticipatory stress without changing recovery-phase cortisol, or affect one physiological axis while leaving another unchanged. Studies that collect a morning cortisol sample, a post-stressor sample, and an inflammatory marker are not interchangeable. The timing is part of the endpoint.

Phase-specific effects may explain some of the heterogeneity in the 89-trial review. They also leave the proposed common mechanism unsettled. Parasympathetic activity and reduced hypothalamic-pituitary-adrenal (HPA) activation are plausible contributors, but biomarker shifts alone do not prove either mechanism.

Replication across settings broadens the signal

Several randomized trials point in the same general direction in distinct populations. In Parkinson's disease, a 2025 trial by Kwok et al. reported lower cortisol and IL-6 after meditation and yoga. A multicenter trial in pregnant women found that mindfulness training reduced pregnancy stress and produced measurable HPA-axis effects; see Wang et al. 2023.

An eight-week randomized trial in healthcare workers during the COVID-19 pandemic combined anulom vilom pranayama with Heartfulness meditation and measured psychological stress, autonomic function, inflammatory biomarkers, and oxidative stress. Sharma et al. 2024 adds useful duration data, but its whole-program setting makes clean attribution difficult: changes in routines, sleep, social context, and work conditions may have contributed.

In Crohn's disease, both cognitive behavioral therapy and mindfulness affected markers of brain-immune-axis regulation in a randomized trial. Nemirovsky et al. therefore support disease-context-dependent modulation, not broad immunosuppression. That distinction matters for anyone tempted to describe meditation as an immune "booster" or "suppressor." The immune system is neither a thermostat nor a houseplant.

Specific mindfulness effects remain hard to isolate

Active comparators are the cleanest test of whether a practice has benefits beyond general care and expectation. In veterans with post-traumatic stress disorder, Shapira et al. compared mindfulness-based stress reduction with present-centered group therapy, an active group treatment that also offers contact, structure, and support. Such designs usually shrink the apparent advantage over mindfulness compared with waitlist or treatment-as-usual studies.

Another challenge comes from outside the conventional mind-body category. A two-week randomized digital-detox study in medical students reported reductions in cortisol, CRP, and IL-6 alongside HRV changes. Farrukh et al. 2025 does not show that digital detox and meditation are interchangeable. It does show that several of the same biomarkers respond to behavioral stress reduction without formal meditation, yoga, or mindfulness training.

What dose is defensible?

Eight weeks is the most defensible practical benchmark in this evidence, because multiple randomized programs have used that schedule. It is not a proven minimum effective dose. Brief interventions can change cortisol or heart rate, while brief protocols have not reliably changed HRV in palliative populations. A short intensive mindfulness retreat studied by Gardi et al. also shifted biological stress and inflammation markers, suggesting that accumulated practice time may matter as much as calendar duration.

BDNF deserves particular caution. The available BDNF findings come largely from clinical neurological contexts. For example, the MindFit stroke trial randomized 141 people with chronic stroke to mindfulness-based stress reduction plus computerized cognitive training, physical exercise plus training, or training alone for 12 weeks. Its multimodal design, described by Bermudo-Gallaguet et al., cannot isolate mindfulness as the source of any BDNF change. Claims that a standard mindfulness app reliably raises BDNF in healthy adults run ahead of this evidence.

The practical verdict

Structured mind-body practice is a reasonable low-risk way to target perceived stress and may modestly shift cortisol and inflammatory biomarkers over time. An eight-week program is a sensible starting point if you want an evidence-based schedule. Choose the format you will actually practice: mindfulness, yoga, breathing exercises, music-based relaxation, or another structured approach that reduces arousal and fits your life.

Keep the promise proportionate. The evidence does not calibrate these effects against statins, anti-inflammatory drugs, or other medical treatments, and it does not establish clinical disease prevention from biomarker changes. It does show a replicated, heterogeneous biological signal that becomes less specific when researchers compare mind-body programs with credible active alternatives.